|
Aug 28
|
BridgeBio Pharma to Participate in September Investor Events
|
|
Aug 26
|
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
|
|
Jul 23
|
BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
|
|
Jun 27
|
BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
|
|
Jun 18
|
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
|
|
May 29
|
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
|
May 24
|
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
|
|
May 22
|
Party Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings Forecasts
|
|
May 14
|
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
|
|
May 13
|
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sen...
|
|
May 4
|
What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
|
|
May 3
|
BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
|
|
May 3
|
BridgeBio Oncology Therapeutics launches with $200m funding
|
|
May 2
|
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
|
|
May 2
|
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
|
|
May 2
|
BridgeBio spinout launches with $200M for KRAS cancer drugs
|
|
May 1
|
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
|
|
Apr 25
|
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 7
|
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
|
Mar 27
|
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
|